Production (Stage)
CytomX Therapeutics, Inc.
CTMX
$2.71
-$0.04-1.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 23.53M | 18.88M | 5.74M | -6.53M | 13.79M |
| Total Depreciation and Amortization | 385.00K | 413.00K | 429.00K | 459.00K | 467.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.64M | 2.26M | 1.81M | 1.45M | 1.03M |
| Change in Net Operating Assets | -47.59M | -41.46M | -28.70M | -14.93M | -41.33M |
| Cash from Operations | -21.04M | -19.91M | -20.73M | -19.55M | -26.05M |
| Capital Expenditure | -119.00K | -80.00K | -19.00K | -96.00K | -115.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.72M | 15.22M | 18.19M | 21.61M | 45.00M |
| Cash from Investing | 30.60M | 15.14M | 18.17M | 21.51M | 44.89M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 2.25M | 0.00 | 5.10M | 174.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 2.25M | 0.00 | 5.10M | 174.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 9.55M | -2.52M | -2.56M | 7.06M | 19.01M |